Clinical trials: Corneal Neovascularisation
Corneal Neovascularization
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation.
- Trial name
- NCT00769145
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Miami
Corneal Neovascularisation
Strategies for Management of Corneal Neovascularisation
The cornea is the transparent window of the eye, which allows light to enter into the eye and also contributes to the focusing of the light rays.
- Trial name
- NCT02594423
- Testing
- Fine Needle Diathermy, Bevacizumab
- Volunteers
- 40 people
- Sponsor
- University of Nottingham
Limbal Stem Cell Deficiency
Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft
The main aim of the study is to determine the safety and feasibility of a cultivated autologous limbal epithelial cell (CALEC) transplantation in the treatment of limbal stem cell deficiency.
- Trial name
- CALEC (NCT02592330)
- Testing
- Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Corneal Neovascularization
Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
The goal of this current study is to prospectively evaluate the influence of a single subconjunctival aflibercept injection on the regression of corneal neovascularization.
- Trial name
- NCT02797704
- Testing
- Aflibercept
- Where
- Israel
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Rabin Medical Center
Corneal Neovascularization
Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
The cornea is the clear front part of the eye. Corneal neovascularization, the excessive growth of blood vessels into the cornea, is a sight-threatening condition.
- Trial name
- NCT01868360
- Testing
- Subconjunctival aflibercept
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Balamurali Ambati
Corneal Newvessels
Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea
Corneal newvessels may arise from a fan of pathologies, inducing long-standing corneal opacification requiring keratoplasty. These last years, VEGF inhibitors have been designed to reduce newascularization induced by gastric…
- Trial name
- BECONNEC (NCT01501760)
- Testing
- bevacizumab, NaCl
- Where
- 5 sites in France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Limoges
Corneal Neovascularisation
Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization
The goal of this clinical trial is to evaluate the efficacy and safety of combined fine-needle diathermy and subconjunctival Bevacizumab injection in patients with corneal neovascularization.
- Trial name
- FND-CNV (NCT07642960)
- Testing
- Fine-needle diathermy, Bevacizumab
- Where
- Vietnam
- Volunteers
- 51 people
- Sponsor
- HoChiMinh City Eye Hospital
Corneal Neovascularization
Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization
To determine the effect of subconjunctival Bevacizumab in corneal neovascularization
- Trial name
- NCT00555594
- Testing
- Bevacizumab (Avastin)
- Where
- Mexico
- Volunteers
- 18 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Corneal Transplant
Neovascularization Patterns in Corneal Graft Rejection
Corneal transplantation is the most commonly performed human tissue transplant worldwide. Over 40,000 corneal transplants occur in the US each year. .
- Trial name
- NCT01695655
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Michigan
Corneal Neovascularization
Corneal Crosslinking for Treatment of Corneal Neovascularization
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
- Trial name
- NCT04787471
- Testing
- 30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1%
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Price Vision Group
Rare Diseases, Aniridia
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
The cross-sectional observational clinical study related to rare eye diseases is a multi-center study in which the hypothesis is that neurokinin 1 receptor and/or substance P expression is increased in REDs associated with…
- Conditions
- Rare Diseases, Aniridia, Neurotrophic Keratopathy, Limbal Stem Cell Deficiency
- Trial name
- NCT06412718
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- IRCCS Ospedale San Raffaele
Corneal Neovascularization
Treatment of Corneal Neovascularization With Topical Pazopanib
The purpose of this study is to determine the safety and efficacy of a drug [Pazopanib (Votrient)] as a treatment for corneal neovascularization.
- Trial name
- NCT01257750
- Testing
- Pazopanib (5mg/ml)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Reza Dana, MD
Corneal Neovascularization
The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization
KDR2-2, as a tyrosine kinase inhibitor, has a strong inhibitory effect on VEGFR2 and a moderate inhibitory effect on PDGFR-β. It can be used for the treatment of corneal neovascularization.
- Trial name
- NCT05011916
- Testing
- KDR2-2 suspension eye drops
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Corneal Neovascularization, Corneal Graft Failure
Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions
The purpose of the study is to test the investigational drug Gamunex-C on the growth of blood vessels over the cornea. This study is being conducted by Dr. Balamurali Ambati at the Moran Eye Center at the University of Utah.
- Conditions
- Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation
- Trial name
- NCT02042027
- Testing
- Gamunex-C
- Where
- United States
- Sponsor
- University of Utah
Corneal Neovascularization
Photodynamic Therapy With Verteporfin for Corneal Neovascularization
Purpose: To investigate the efficacy of photodynamic therapy with verteporfin for the treatment of patients with corneal neovascularization. Design: Prospective, non-comparative case series.
- Trial name
- NCT00471406
- Testing
- Photodynamic Therapy with Verteporfin
- Sponsor
- Chonnam National University Hospital
Corneal Neovascularization
Corneal Thinning During Topical Bevacizumab Therapy
The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.
- Trial name
- NCT00515684
- Testing
- bevacizumab (Avastin)
- Where
- South Korea
- Sponsor
- Yonsei University
Corneal Neovascularization
Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.
- Trial name
- NCT00681889
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Reza Dana, MD
Corneal Neovascularization
Bevacizumab for the Treatment of Corneal Neovascularization
The purpose of the current study is to assess the efficacy and safety of the inhibitory effect of bevacizumab (Avastin) with different routes including topical and subconjunctival application on corneal neovascularization in the…
- Trial name
- NCT00992849
- Testing
- Bevacizumab
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Chang Gung Memorial Hospital
Corneal Neovascularization, Corneal Graft Failure
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
The leading risk factor for corneal transplant rejection is abnormal blood vessel growth of the host bed. Vascular endothelial growth factor (VEGF) is thought to be a mediator of this corneal neovascularization (NV), therefore we…
- Trial name
- NCT01072357
- Testing
- Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Reza Dana, MD
Corneal Neovascularization
An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization
The first stage of this study will evaluates the tolerability of different concentrations of Conbercept eye drop to patients with corneal neovascularization.
- Trial name
- NCT04215393
- Testing
- Conbercept eye drop
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.